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Abstract
We used a novel method based on allele-specific quantitative polymerase chain reaction (Intplex) for the analysis of
circulating cell–free DNA (ccfDNA) to compare total ccfDNA and KRAS- or BRAF-mutated ccfDNA concentrations in
blood samples frommice xenografted with the human SW620 colorectal cancer (CRC) cell line and from patients with
CRC. Intplex enables single-copy detection of variant alleles down to a sensitivity of≥0.005 mutant to wild-type ratio.
The proportion of mutant allele corresponding to the percentage of tumor-derived ccfDNA was elevated in xeno-
grafted mice with KRAS homozygous mutation and varied highly from 0.13% to 68.7% in samples from mutation-
positive CRC patients (n = 38). Mutant ccfDNA alleles were quantified in the plasma of every patient at stages II/III
and IV with a mean of 8.4% (median, 8.4%) and 21.8% (median, 12.4%), respectively. Twelve of 38 (31.6%) and 5
of 38 (13.2%) samples showed a mutation load higher than 25% and 50%, respectively. This suggests that an impor-
tant part of ccfDNA may originate from tumor cells. In addition, we observed that tumor-derived (mutant) ccfDNA
was more fragmented than ccfDNA from normal tissues. This observation suggests that the form of tumor-derived
and normal ccfDNA could differ. Our approach revealed that allelic dilution is much less pronounced than previously
stated, considerably facilitating the noninvasive molecular analysis of tumors.
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Introduction
KRAS is an essential activator within the signaling cascade induced by
the activation of the endothelial growth factor receptor (EGFR) gene. KRAS
plays a central role in tumor development by regulating the expression of
the proteins that are involved in cell proliferation and survival, metastatic
spread, and angiogenesis. KRAS point mutations lead to a constitutively
active guanosine triphosphate (GTP)-bound protein that confers the sig-
nal to BRAF and the subsequent downstream activation of the mitogen-
activated protein kinase (MAPK) pathway. The presence of some KRAS
point mutations leads to its constitutional activation and renders the
treatment of colorectal cancer (CRC) patients with potent inhibitors of
EGFR, such as cetuximab and panitumumab, ineffective [1]. Therefore,
all patients eligible for anti-EGFR treatments must first be tested for
KRASmutations (present in 35–45% of CRC cases) before starting such
therapies. BRAF point mutations in CRC cells (8–14% of CRC cases)
might also cause resistance to targeted therapies. BRAF and KRASmuta-
tions are considered as mutually exclusive in CRC [2]. Although the
detection of BRAF mutations is also associated with poorer prognosis
[3,4], the BRAF mutational status has not been incorporated into the
treatment guidelines in force because of conflicting results among studies.
Currently, analysis of the KRAS mutational status of a patient is carried
out from tumor sections by various methods including sequencing. It
represents one of the first molecular assessments of personalized medi-
cine in oncology. BRAF V600E mutation is examined in the case of
a negative KRAS mutation status in several national guidelines, thus
enlarging the targeted therapy–resistant patient population stratum.
Significant amounts of circulating cell–free DNA (ccfDNA) are pres-
ent in the plasma of cancer patients [5,6]. As blood analysis of ccfDNA
is easy to set up and relatively noninvasive, ccfDNA represents a very
attractive tool for detecting the presence of mutations. ccfDNA dy-
namics can be easily modeled using xenografted mice [7,8]. Plasma
ccfDNA in cancer patients may originate from three sources: 1) healthy
normal cells, 2) tumor stromal cells, and 3) tumor cells [9]. A partial
overlap in the ccfDNA level between healthy individuals and cancer
patients has been observed in the literature [10,11]. Quantification
of ccfDNA exclusively derived from tumor cells represents an obvious
interest with regard to monitoring or following up tumor progression
in the course of cancer patient management. Only a few reports have
described the systematic quantification of tumor-derived ccfDNA
[12–16] based on assays for quantifying ccfDNA harboring the point
mutation that characterizes the tumor. Thus, mutant ccfDNA has
been found previously as a tiny fraction of the total ccfDNA [13–15].
We have previously demonstrated that quantifying ccfDNA by
quantitative polymerase chain reaction (Q-PCR) analysis is largely
dependent on the target size [17]: The ccfDNA size pattern can dis-
criminate plasma from CRC patients and from plasma from healthy
individuals [18]. From these observations, we set up a Q-PCR–based
method that demonstrated the unprecedented sensitivity and specificity
of quantifying mutant ccfDNA. In this study, we determined the pro-
portion of mutant (tumor cell–derived) alleles from ccfDNA analysis
in a CRC mouse xenograft model and in 38 CRC patient plasma sam-
ples. The results are related to the as-yet-unknown contribution of the
ccfDNA cell or tissue origins.
Materials and Methods
Cell Lines
The human colorectal adenocarcinoma HCT-116, SW620, LS174T,
SW1116, and HT29, the human lung adenocarcinoma A549, and
the human pancreatic MiaPaca2 cell lines were obtained from ATCC
(Manassas, VA). They were grown in RPMI 1640 supplemented with
10% fetal calf serum and 2 mmol/l L-glutamine at 37°C in a humidified
atmosphere with 5% CO2.
Mouse Xenograft Model
Female athymic nude mice (6–8 weeks of age, n = 8) were xeno-
grafted with human SW620 CRC cells as previously described [18].
Three nude mice were not grafted and were used as controls. The
mice were sacrificed using CO2. Blood collection and tumor weighing
were carried out at different times post graft. All experiments were
performed by an accredited person (Dr B. ROBERT, No. 34-156)
and they complied with the current national and institutional regulations
and ethical guidelines.
Human Blood Samples
Blood samples were collected from patients (n = 38) with CRC
(metastatic or not), irrespective of their CRC stage or relapse (stage IV,
n = 33; stage III, n = 1; stage II, n = 4). CRC patients did not receive
chemotherapy or radiotherapy for at least 1 month before the blood
collection. The clinical features [Tumor Nodule Metastasis (TNM)
staging] and the treatment for each CRC patient in this study before
blood collection are summarized in Tables 1 and W1, respectively.
Positive mutation status was retrospectively or prospectively carried out
in tissue (primary tumor or metastasis) in the context of the standard
management care of CRC patients. All plasma samples included in this
study were analyzed correctly (100% success rate). Plasma analysis was
performed in a blinded manner and only once for each of the 38 patients
considered for treatment or surgery. Written, informed consent was ob-
tained from all participants before the onset of the study. The protocols
for the use of blood samples from healthy volunteers used in this study
were approved by the “Etablissement Français du Sang” Ethics Com-
mittee (EFS-PM agreement: 21/PVNT/MTP/CNR14/2010-0029).
Plasma Isolation and ccfDNA Extraction
Blood samples were collected in EDTA tubes: 2 ml of blood was col-
lected from human patients and 0.8 to 1 ml from mice. The blood was
centrifuged at 1200g at 4°C in a Heraeus Multifuge LR centrifuge for
10 minutes. The supernatants were isolated in sterile 1.5-ml Eppendorf
tubes and centrifuged at 16,000g at 4°C for 10 minutes. Subsequently,
the supernatants were either immediately handled for DNA extraction
or stored at −80°C. ccfDNA was extracted from 1 ml of plasma using
the QIAmp DNA Mini Blood Kit (Qiagen, Hilden, Germany) accord-
ing to the “Blood and body fluid protocol.” DNA samples were kept at
−20°C until use.
ccfDNA Quantification by Q-PCR
The methodology and the data description were carried out accord-
ing to the MIQE guidelines [19]. Q-PCR amplifications were carried
out at least in duplicate in a 25-μl reaction volume on a Chromo4
instrument using the MJ Opticon Monitor 3 software (Bio-Rad, Her-
cules, CA). Each PCR mixture was composed of 12.5 μl of PCR mix
(Bio-Rad Supermix SYBR Green), 2.5 μl of each amplification primer
(0.3 pmol/μl), 2.5 μl of PCR-analyzed water, and 5 μl of DNA extract.
Thermal cycling consisted of three repeated steps: a 3-minute hot-start
polymerase activation-denaturation step at 95°C followed by 40 re-
peated cycles at 95°C for 10 seconds and then at 60°C for 30 seconds.
Melting curves were obtained by increasing the temperature from 55 to
90°C with a plate reading every 0.2°C.
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Serial dilutions of genomic DNA from human placenta cells (Sigma,
Munich, Germany) were used as standard for quantification and their
concentration and quality was assessed using a Nanodrop spectro-
photometer (Thermo Scientific, Wilmington, DE). Each sample was
analyzed in duplicate or in triplicate and each assay was repeated at least
once. The ccfDNA concentrations obtained with each primer set were
normalized to the precise concentration of a genomic DNA sample
amplified using the same primer set. The coefficient of variation of the
concentration value due to ccfDNA extraction and Q-PCR analysis was
calculated as 24% from two experiments (n = 12). Quantification of
murine- or human-derived ccfDNA in our experimental mouse model
was performed by using the primer systems described in Table W2.
Intplex Mutation Analysis
We established an allele-specific blocker [20] Q-PCR–based method
specific for ccfDNA analysis (named Intplex) to enable the detection
of point mutation and to determine mutant allele concentration. This
method combined the use of 1) allele-specific Q-PCR with blocking
3′-phosphate–modified oligonucleotide [20], 2) low Tm primers with
mutation in 3′, 3) an integrated primer design, 4) routine internal
positive and negative controls, and 5) optimal analytical procedures.
The blocking oligonucleotides were modified by adding a phosphate
group in the 3′ extremity to increase the specificity of Q-PCR by block-
ing the nonspecific extension of wild-type (WT) sequences. Mutational
status was determined by detection of the specific amplification of the
mutant sequence through melting analysis: only samples with amplifi-
cation showing Tm within a 0.4°C range compared to the internal
positive control from mutated cell line DNA was designated as positive
for the mutation. The concentration was calculated from Cq detected
by Q-PCR and a control standard curve on DNA of known concen-
tration and copy number (Sigma-Aldrich). Each concentration of
sample used for standard curve was controlled by nanodrop evaluation.
Intplex primer system design is presented in Figure 1. The concen-
tration obtained when targeting the mutated sequence corresponds
to the concentration of the alleles bearing the mutation (mA). The
concentration obtained when targeting the WT sequence located at
300 bp from the position of the point mutation corresponds to total
ccfDNA (WT + mutated ccfDNA) and is called refA. The propor-
tion of mutant allele (mA%) was determined by quantifying the rela-
tive ratios between mA and refA (Figure 1).
We adapted Intplex for the detection of the KRAS hot-spot muta-
tions at the 2nd exon (G12V, G12A, G12D, G12S, G12C, and
G13D), which combined corresponds to 96% of KRAS-mutated
tumors in CRC (Cosmic Sanger analysis), and also for the detection
of the human BRAF 15th exon sequence containing the V600E point
mutation, which corresponds to 97.8% of BRAF-mutated tumors
in CRC (Cosmic Sanger analysis). The proportion of mutant allele
(mA%) was determined for the fragments >60 to 64 bp for KRAS
and >97 bp for BRAF (Figure 1).
Figure 1. Primer designs used in the study: primers targeting a KRAS
region (A) or a BRAF region (B) for quantifying ccfDNA WT and
mutated concentrations.
Table 1. Determination by Q-PCR of the ccfDNA Concentration (refA) and of the Proportion of
Mutant Allele (mA%) in Plasma Samples from CRC Patients with KRAS- or BRAF-Mutated Tumors.
Sample TNM Status Mutation refA (ng/ml Plasma) mA%
CRC1 T3N0M0 G13D 2.6 12.69
CRC2 T3N2M1 G12V 32.5 0.89
CRC3 T0N0M1 G12D 24.6 7.67
CRC4 T0N0M1 G12A 167 32.76
CRC5 T4N2M1 BRAF V600E 177.9 46.22
CRC6 T3N2M1 G12D 55.9 64
CRC7 T0N0M1 BRAF V600E 359.3 44.77
CRC8 T3N0M0 BRAF V600E 25.3 5
CRC9 T3N2M1 G13D 28.2 4.05
CRC10 T0N0M1 BRAF V600E 15.4 10
CRC11 T4N2M1 G12S 47.3 12.04
CRC12 T3N2M1 BRAF V600E 45.2 10.72
CRC13 T3N2M1 G12C 143.3 2.56
CRC14 T3N2M1 BRAF V600E 31 26.6
CRC15 T3N2M1 G12C 23.7 0.332
CRC16 T3N2M1 G13D 41.7 13.12
CRC17 T4N2M1 G12S 160.9 43.5
CRC18 T4N2M1 G12V 14.9 1.73
CRC19 T4N2M1 G13D 175.8 64.16
CRC20 T4N2M1 G13D 89.8 18
CRC21 T4N2M1 G12V 200.5 4.57
CRC22 T3N2M1 G13D 25.1 12.18
CRC23 T3N0M1 G13D 21 0.711
CRC24 T0N0M1 G12V 544 17.5
CRC25 T0N0M1 G12D 1386.9 36.6
CRC26 T3N2M1 G13D 42.2 4.15
CRC27 T4N1M0 G12S 29.4 8.36
CRC28 T3N0M0 G13D 13.1 6.62
CRC29 T3N0M1 G12V 13.6 6.59
CRC30 T4N0M1 G13D 10.3 56.36
CRC31 T4N0M1 G12A 25.1 8.5
CRC32 T4N0M1 G12V 6.2 68.77
CRC33 T4N0M0 G12A 23.9 9.26
CRC34 T4N0M1 G12D 47.1 9.51
CRC35 T4N0M1 G12D 36.1 29.18
CRC36 T4N0M1 G13D 87.2 56.91
CRC37 T3NxM1 G12V 6.7 5.05
CRC38 T3NxM1 G13D 220.7 0.13
Mutational status was confirmed by tumor section analysis as described in Materials and Methods
section. TNM represents the Tumor Nodule Metastasis classification. refA corresponds to the total
allele concentration (in ng/ml plasma) of a reference allele (Figure 1). mA% was calculated as the
percentage of mutant allele from refA.
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Positive control DNA was extracted from cell lines bearing the KRAS
and BRAFmutations. The respective correspondence between cell lines
and the corresponding mutation was further detailed: HCT-116 for the
G13D KRAS mutation, SW620 for the G12V KRAS mutation, A549
for the G12S KRASmutation, LS174T for the G12D KRASmutation,
MiaPaca2 for the G12C mutation, SW1116 for the G12A KRAS
mutation, and HT29 for the V600E BRAF mutation.
Every mutational status, summarized in Table 1, was further vali-
dated by comparing it with that obtained from the genomic DNA
analysis of tumor sections by either sequencing (>50% of tumor cells)
or by high resolution melt (HRM) and pyrosequencing (20% to 50%
of tumor cells) [21].
Sensitivity and Specificity Analysis of the Quantification
of Mutant ccfDNA
Evaluation of the sensitivity level of our method was first conducted
on genomic DNA. DNA from cells harboring a specific mutation was
serially diluted six times into high concentrated WT genomic DNA
from human placenta (Sigma-Aldrich) up to dilution of 0.2 mutated
copies in 20,000 copies (1/100,000 ratio). All the experimental points
were obtained in triplicate.
Primer Design
The sequences and characteristics of the selected primers are pre-
sented in Table W2. The primers were designed using the Primer 3
software and all sequences were checked for self-molecular or inter-
molecular annealing with nucleic acid folding software (mfold and
oligoAnalyzer 1.2). We performed local alignment analyses with the
BLAST program to confirm the specificity of the designed primers.
Oligonucleotides were synthesized and purified on high performance
liquid chromatography (HPLC) by Eurofins (Ebersberg, Germany)
and quality control of the oligonucleotides was performed by matrix-
assisted laser desorption ionization–time of flight (MALDI-TOF).
ccfDNA Size Allele Analysis
We used a set of primers that amplifies targets of increasing size (82,
138, 200, 300, 355, and 390 bp) within the hot-spot region of the
KRAS gene (codons 12 and 13 of exon 2) and in which the forward
primer of each primer pair specifically targets a point mutation of this
region or the WT sequence (Table W2 and Figure W1). Therefore,
the concentration of the allele bearing either the point mutation (mA)
or not (wtA) was directly compared to the ccfDNA fragment size. The
plasma of the CRC patients with KRAS G13D (CRC1) and KRAS
G12D (CRC3 and CRC6) mutations was examined. The efficiency of
the PCR primer system was normalized with known amount of genomic
DNA (in ng) from cell lines harboring KRASG12D (LS174T) or G13D
(HCT116) mutations.
Integrity Index Analyses
Intplex method allowed calculation of the ccfDNA integrity index.
The degree of ccfDNA integrity was assessed by calculating an index
we termed the DNA integrity index (DII). The DII was determined
by calculating the ratio of the concentration determined by using the
primer set amplifying the large (circa 300 bp) target to the concentration
determined by using the primer set amplifying the short (<100 bp)
target (Figure 1).
Results
Sensitive and Specific Quantification of Mutant ccfDNA
by a Q-PCR–Based Method
We set up a Q-PCR method combining several refinements for
allele-specific discrimination and a primer system design specific to
ccfDNA. The integrated primer design of our test involves amplifica-
tion at the extremities of a 300-bp region of two shorter regions of the
same size (in the range of 60–100 bp, ±10%), one corresponding to a
mutated sequence and another to a WT sequence (Figure 1, A and B).
We demonstrated previously the crucial importance of the primer set
design by demonstrating that ccfDNA quantification by Q-PCR is
much higher and more accurate when amplifying regions shorter than
100 bp [18]. Varying PCR target size of both short amplicons of more
than 10% generates detectable differences between the determined
respective ccfDNA amounts. Serial dilutions of mutant DNA to WT
ratio revealed detection of the mutant at a level of 1/25,000 for each
KRAS and BRAF mutation, as illustrated in Figure W2. Intplex
enables single-copy detection of variant alleles down to a sensitivity of
≥0.005% mutant to WT ratio.
As a result, this system design allows the accurate determination of
the percentage of mutant allele (mA%). In this study, the lowest mA%
found in mCRC plasma was 0.13% (Table 1).
Up to 63% of Total ccfDNA in Mice Xenografted with
Cells Harboring a Homozygous KRAS G12V Mutation
Originates from Tumors
We used athymic nude mice xenografted with human SW620 CRC
cells to clearly distinguish between nontumor-derived (mouse origin)
and mutated or nonmutated tumor-derived (human origin) ccfDNA
(Figure 2 and Table W3). These cells were homozygous for the KRAS
Figure 2. Quantification by Q-PCR of ccfDNA derived from malignant and nonmalignant cells in the mouse model. Tumor weight is
represented by the red curve (right axis). (A) Concentration of ccfDNA derived from mouse (normal) cells (mWT ccfDNA) in control
(not grafted) mice (Mouse Nos. 1–3) and in athymic nude mice (Mouse Nos. 4–11) xenografted with the SW620 colorectal human cells,
determined using a primer set targeting a mouse KRAS second intron WT sequence (Table W2). (B) Concentration of ccfDNA derived
from human cells (hWT ccfDNA) using a primer set targeting a human KRAS second intron WT sequence. (C) Concentration of ccfDNA
derived from human cells (hBRAFm ccfDNA) using a primer set targeting a human BRAF 15th exon sequence containing the V600E
point mutation (Table W2). (D) Concentration of ccfDNA derived from human cells (hKRASm ccfDNA) using a primer set targeting a
human KRAS second exon sequence that contains the G12V point mutation. (E) Concentration of total ccfDNA (mWT ccfDNA +
hWT ccfDNA). (F) Proportion of hKRASm ccfDNA in total ccfDNA. (G) Proportion of tumor-derived ccfDNA and KRAS-mutated tumor-
derived ccfDNA versus nontumor-derived ccfDNA expressed as the percentage of the total ccfDNA (derived from both mouse and
human cells as quantified here). Concentration values are described in Table W3.
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G12V mutation. We first confirmed several observations that we have
described previously [18]: 1) the nontumor-derived ccfDNA amount
in mouse plasma (Figure 2A) did not vary with tumor size, 2) the
control mouse ccfDNA amount (mean, 8.6 ± 3.8 ng/ml; median,
6.6 ng/ml) was similar to the nontumor-derived ccfDNA amount
(mean, 7.4 ± 2.6 ng/ml; median, 7.5 ng/ml; Figure 2A), 3) the
tumor-derived ccfDNA amount appeared to increase with tumor size
(Figure 2, B and D), and 4) no ccfDNA was detected when targeting
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the BRAF V600E point mutation (Figure 2C), highlighting the high
specificity of our analysis to quantify and detect the presence of
ccfDNA alleles with a specific point mutation.
Moreover, our data showed that the amount of the ccfDNA derived
from the tumor, as determined when targeting the human KRAS
second intron, was found to be somewhat similar to the amount of
human KRAS second exon G12V-mutated ccfDNA (Figure 2, B
and D). This observation was consistent both with the clonogenic
property of the SW620 cells used for the xenografts and with the
same allele being carried by each member of the pair of homologous
chromosomes in these cells (homozygous mutation). In addition, this
demonstrates consequently that our method for determining the con-
centration of KRAS second exon G12V-mutated ccfDNA was accu-
rate. Tumor-derived ccfDNA represented a prevalent proportion
(35–44%) of the total ccfDNA concentration (derived from both
mouse and human cells, as quantified in this study) in mice bearing
tumors between 100 and 500 mg in weight; this amount ranged from
44% to 63% in mice with 500 to 1200 mg of tumors (Figure 2,
E–G). Hence, we concluded that more than half of the total concen-
tration of ccfDNA in xenografted mice may be derived from the
tumor, which can be quantified by detecting KRAS-mutant ccfDNA.
0.13% to 69% of KRAS-Mutant Allele Was Observed in
ccfDNA from the Plasma of KRAS-Mutated CRC Patients
On the basis of these results, we examined the quantification of
selected KRAS- and BRAF-mutated ccfDNA in the plasma of CRC
patients. Table 1 and Figure 3 present the mutation detection and
the percentage of mutated ccfDNA that we found in 38 plasma samples.
This number of KRAS/BRAF-mutated samples could correspond to a
nonselected cohort of 85 to 95 (negative and positive) CRC patient
blood samples. The mutational status of all samples was further validated
by comparing it with that obtained from the genomic DNA analysis of
the tumor section either by sequencing or by HRM and pyrosequenc-
ing. Hence, mutant ccfDNA alleles could be quantified in the plasma
of every patient at stages II, III, and IV (Table 1). The proportion of
mutated ccfDNA alleles varied from 0.13% to 68.8% (mean, 20.05%;
median, 10.36%) and, more precisely, at stages II and III (mean, 8.39%;
median, 8.36%; n = 5) and at stage IV (mean, 21.81%; median,
12.04%; n = 33). Note that we found six plasma samples with 5% to
46.22% ccfDNA bearing the BRAF V600E point mutation.
The KRAS-Mutated and WT ccfDNA Fragment Size
Profiles Markedly Differ
We observed previously that the total ccfDNA from the CRC
patients’ plasma is much more fragmented than that from healthy indi-
viduals [18]. Since our preliminary results revealed a high proportion
of tumor-derived ccfDNA, we examined its size pattern in comparison
with nontumor-derived ccfDNA from CRC patients (Figure 4). The
size profile of the ccfDNA fragments bearing a mutation detected in
CRC6, CRC3, and CRC1 plasma was similar. Similarity in the size
profile was also observed in these three CRC plasmas when detecting
the WT sequence. In all cases, the concentration of ccfDNA was cor-
related inversely with the amplicon size. It appeared very low or non-
detectable when targeting 355 and 390 bp. Note that the sum of wtA
and mA was 92%, 54%, and 146% of refA (Figure 4), suggesting a
somewhat equivalency between wtA + mA and refA, inasmuch as the
coefficient of variation of the plasma ccfDNA concentration as deter-
mined by our method was calculated as 24%.
Subsequently, we determined the percentage of mutant ccfDNA
(mA%) relative to refA by using the primer set described in Figure 1B.
mA% was 26.6%, 17.4%, and 20.6% in CRC6, CRC3, and CRC1,
respectively (Figure 5), which confirmed the results determined with
the primer set that amplified two 60-bp sequences in the same region
of the KRAS exon 2 (Figure 1 and Table 1). Schmidt and Diehl [22]
found that high fragmentation was not due to the storage conditions
or the procedure used to prepare the samples.
Figure 3. Histogram of the proportion of mutant allele (mA%) in plasma samples from CRC patients with KRAS- or BRAF-mutated tumor.
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Furthermore, among the 82- to 138-bp ccfDNA fragments, very few
WT fragments (Table 2) were observed in contrast to the very high
proportion of mutant fragments (70.1%, 74.0%, and 89.3% in
CRC6, CRC3, and CRC1, respectively; Figure 5). This was confirmed
by using the plasma sample of anotherCRCpatient harboring theKRAS
G12Vmutation (CRC2) in which 52.1% of the 82- to 138-bp ccfDNA
fragments carried the mutation (Figure 5). By quantifying the propor-
tion of KRAS-mutated ccfDNA, we demonstrated that tumor-derived
ccfDNA could be discriminated from ccfDNA originating from non-
malignant cells, assuming that the mutant allele is in great excess
among all tumor malignant cells [23].
Discussion
The Mutation Loads in the Xenografted Mouse Animal
Model and in CRC Plasma Differ Markedly
ccfDNA analysis showed the very high proportion of mutant allele
(up to 63%) present in xenografted mice and demonstrated that the
mutant tumor-derived ccfDNA amount corresponds to the total tumor-
derived ccfDNA amount. This suggests tumor cell clonogenicity and
a very low proportion of tumor microenvironment surrounding cells.
These observations highlight some of the crucial differences between
this experimental mouse model and the clinical setting when compared
with our data on CRC plasma samples, which showed, in some cases,
a very low proportion of the mutant allele.
The Mutation Load in CRC Patients’ Plasma Is
Highly Variable
Only two papers from the same group based on a cohort study and
another two based on one case report have reported previously the
examination of the proportion of mutant ccfDNA alleles among total
circulating DNA alleles. Diehl et al. [13–15] developed a highly sen-
sitive approach (BEAMing) to detect and quantify ccfDNA harbor-
ing APC mutations in CRC patients’ plasma samples [13]. Assuming
that they calculated the mutant APC fragment percentage as the mA%
value, they detected lower amounts of mutant allele (median of 0.04%
for samples from patients with Dukes A, n = 8; 1.28% for patients
with Dukes B, n = 8; and 8.05% for patients with Dukes D, n = 6,
cancers) in comparison with our data. In another study, this group
evaluated the median percentage of mutant allele as 0.18% in plasma
from 16 Dukes D CRC patients [14,15]. Furthermore, only 0.3% of
ccfDNA with the KRAS G12V mutation was detected in the plasma
sample from a patient with metastatic CRC using this technique [16].
The high mA% variation observed by this group was confirmed in
our study, despite the higher median values we obtained. In particular,
our study revealed, for the first time, several cases (5 of 38) where more
than half of total ccfDNA amount was mutated (Figure 5). This obser-
vation indicated that, in some cases, ccfDNAmay originate mainly from
tumor cells. Twelve of 38 (31.6%) samples showed a mutation load
higher than 25% (Figure 4). As a consequence, the tumor-derived
ccfDNA did not correspond to “a tiny fraction” as previously stated
[13–16] and it may not have derived mainly from stroma cells.
The higher level of mutation load as observed here may be due to
the use of targeting low size sequence (<100 bp) in exon 2 and exon
15 of KRAS and BRAF, respectively. Targeting low size sequence for
ccfDNA was based on previous work [18] in which a ccfDNA size
distribution study indicated a much higher (four- to six-fold) efficacy
in detecting WT intron fragments (total ccfDNA). The approach of
comparing amplification data of a specific sequence with another
sequence of a similar target size (±10 bp) within a 300-bp region, as
carried out here (Figure 1), enabled the direct comparison between the
concentration of the mutant and the WT KRAS sequence (Figure 5)
and, subsequently, accurate determination of mutation load (Figure 3).
In addition, the combination of allele-specific priming, blocking
of WT unspecific amplification, and melting analysis provides un-
surpassed sensitivity and specificity for a Q-PCR–based method.
Intplex can be adapted to all point mutations of interest.
The higher percentage of mutant ccfDNA detected with our Q-PCR
method may be due to the use of the KRAS and the BRAF muta-
tions as biomarkers and also to our Q-PCR method. Its use revealed
that allelic dilution appears less pronounced than previously stated
[13–15], easing the detection of resistance-associated point mutations
and the quantification of mutant ccfDNA alleles. Alternatively to
the hypothesis of Diehl and Vogelstein [13], the observation of mA%
higher than 25% in more than one-third of the plasma samples
provides evidence that ccfDNA does not originate only from micro-
environment cells but rather that a significant proportion of ccfDNA
could be tumor derived. It was shown that phagocytosis by macro-
phages or other scavenger cells of apoptotic or necrotic neoplastic cells
Figure 4. Comparison of the ccfDNA fragment size distribution of mutant (black bars) and nonmutant (gray bars) ccfDNA in plasma samples
from patients with CRC bearing a point mutation in the KRAS exon 2. Data are expressed as ng of ccfDNA/ml plasma. ccfDNA from the
plasma of patients CRC6 (KRASG12D), CRC3 (KRASG12D), and CRC1 (KRASG13D) was quantified by amplifying KRAS exon 2 sequences of
increasing size (82, 138, 200, 300, 355, and 390 bp; FigureW1 and Table W2). Detection of the resulting amplicons of various sizes enables
quantification of the size fractions of ccfDNA contained in a mononucleosome (180–200 bp) and a dinucleosome (360–380 bp) [27,28].
Plasma of CRC6, CRC3, and CRC1 were chosen because of their high total ccfDNA content and high mutant ccfDNA proportion (Table 1).
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could lead to DNA release in the circulation of patients with cancer
[24]. This seems to occur especially in invasive tumors, which generally
contain large regions of necrosis due principally to hypoxia. Interest-
ingly, the CRC tumor was among the tumors with a higher cell loss
factor (94–98%) [25], which might explain the high ccfDNA level
observed in CRC patients.
mA% was highly variable (0.13–68.77%), as determined from
ccfDNA by Intplex among the positive KRAS or BRAF mutational
status CRC plasma samples (n = 38). This raises crucial questioning
about the cell origin of ccfDNA release, tumor cell composition, and
mutant allele specific imbalance. In CRC patients, we can discriminate
three cells from which the release of ccfDNA originates: 1) malignant
tumor cells, 2) tumor microenvironment cells (stromal, epithelial, or
inflammatory cells), and 3) nontumor-derived cells, which produce the
basal ccfDNA level in healthy individuals (about 5 ng/ml, [18]). The
highest mA% (68.77%) is more than 500-fold greater than the lowest
mA% (0.13%) observed. As it seems unlikely that the proportion of
the microenvironment cells reaches up to more than 90%, the low
mA% observed in a significant proportion of the plasma samples (for
instance, 18/38 being lower than 10%) was not only due to a low
malignant cell proportion but also to poor tumor cell clonogenicity.
West et al. [26] demonstrated that the median proportion of cells from
primary CRC tumors was 57.1% (interquartile range from 47.4% to
66.4%) and 9% at the lowest in pT1 stage cancer.
The proportion of mutated tumor cells within a tumor may be ex-
pressed by the mutation load, which can be determined by quantifying
the number of mutated cells in a tumor section [23,26] or by quan-
tifying the mutant alleles from circulating DNA, as performed in this
study. It depends on the mutation zygosity status, being directly equiv-
alent to the mutant allele percentage in case of homozygosity or being
twice as much as the mutant allele percentage in case of heterozygosity.
We determined through the Cosmic Sanger database and several re-
ports that 25% and none of the colorectal adenocarcinoma tumor
samples that tested positive showed a KRAS and BRAF homozygous
mutation, respectively. Since the zygosity status of the patient tumors
was unknown in our study, we were unable to quantify precisely their
mutation load. Nevertheless, we can assume that the five CRC plasma
samples showing a mutant allele percentage superior to 50% correspond
to a tumor-bearing KRAS homozygous mutation. Given the hetero-
zygosity of the BRAF 600Emutation, the allele mutation load is equiva-
lent to half of the genome-equivalent mutation load, and as a result,
the proportion of malignant cells at least ranged from 10% to 92.4%.
Our data might suggest a very high variation in the proportion of
malignant cells in colorectal tumors and/or low tumor cell clono-
genicity. However, the direct relationship between these data and
the proportion of malignant cells is currently uncertain as the mecha-
nism of ccfDNA release determines the yield (necrosis, apoptosis, or
active release). Therefore, interindividual comparison of the propor-
tion of mutant allele determined from circulating DNA could appear
somewhat more difficult to interpret; however, this parameter could be
an efficient biomarker for monitoring or following up CRC patients
Figure 5. Histogram representation of the various parameters indica-
tive of ccfDNA fragment size pattern. Size fraction is expressed as
a percentage of the highest value obtained in each size set. KRAS
second exon primer systems enable quantification ofmutant ccfDNA
and ccfDNA harboring theWT sequence at themutation location, re-
spectively. Numbers under the histograms: 6, 3, 1, and 2, plasma from
CRC patients with a positive mutational status for KRAS (CRC1–3
and CRC6).
Table 2. Data of the Various Parameters Indicative of ccfDNA Fragment Size Pattern.
Samples Q-PCR Target Fraction Concentration (ng/ml Plasma) DII
<138 138 > x > 300 >300
CRC6 Mutant KRAS second exon 18.75 6.27 1.68 0.06
CRC3 Mutant KRAS second exon 1.69 0.41 0.18 0.08
CRC1 Mutant KRAS second exon 0.26 0.12 0.09 0.05
CRC2 Mutant KRAS second exon 2.25 1.3 0.76 0.18
CRC6 WT KRAS second exon 8.14 59.04 8.91 0.12
CRC3 WT KRAS second exon 0 9.91 1.21 0.11
CRC1 WT KRAS second exon 0 1.9 0.56 0.3
CRC2 WT KRAS second exon 7.27 19.69 12.71 0.32
The proportion of ccfDNA fragment <138 bp was determined by subtracting the concentration
determined by using the primer set amplifying the 82-bp target from the concentration determined
by using the primer set amplifying the 138-bp target (138 bp − 82 bp). Negative values are expressed
arbitrarily as 0. The ccfDNA integrity index (DII) was determined by calculating the ratio of the
concentration determined using the primer set amplifying the 300-bp target to the concentration
determined using the primer set amplifying the 82-bp target.
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and could be combined with size fraction analysis, as demonstrated in
this study, to provide a deeper examination toward this goal.
ccfDNA Size Fraction Analysis Characterizes
Tumor-Derived ccfDNA
ccfDNA is thought to be released through various mechanisms such
as necrosis, phagocytosis, apoptosis, or active release [27]. ccfDNA
seems to be present in the circulation, especially in the form of com-
plexes (through electrostatic bonds) with cell constituents (mono-
nucleosomes or oligonucleosomes or nucleolipoproteins, [28,29]), or
inserted in apoptotic vesicles that make it relatively stable. As apoptosis
leads to high internucleosomal DNA fragmentation, fragments as small
as 180 to 200 bp (the length of mononucleosome DNA) may be found
following this release mechanism [27,28]. Apoptosis results to the re-
lease of shorter fragments compared to necrosis or phagocytosis (larger
than 10,000 bp, [13]); therefore, the estimation of ccfDNA fragmen-
tation could provide evidence on the ccfDNA release mechanism.
To specify cancer patients’ ccfDNA and study its origin, previous
studies have evaluated their fragmentation level. However, as stated
by Jung et al. [30], experimental bias has led to large discrepancies
when drawing general conclusions. Given the ability to quantifying
mutant ccfDNA in this work, we studied various fragmentation in-
dexes. Hence, in addition to the integrity index (corresponding to
the proportion of DNA longer than the length of the mononucleosome
DNA among the total ccfDNA) as previously examined [6,31], the
proportion of various ccfDNA size fractions of the plasma from four
CRC patients with a KRAS point mutation were determined (Figure 5).
In CRC6, CRC3, CRC1, and CRC2 samples, preliminary results in-
dicate thatmutant ccfDNAwas composedmostly of fragments <138bp,
while nonmutant ccfDNA was mostly constituted of fragments in the
138- to 300-bp range and very few fragments <138 bp. Conversely,
Schmidt and Diehl [22] recently observed that mutant ccfDNA has
almost no influence on DNA integrity, indicating that mutant ccfDNA
presents a minor fraction of the total ccfDNA. This highlights the
numerous discrepancies found in the literature on ccfDNA in cancer
patients [30]; in this regard, we proved herein that careful methodology
design with better knowledge of the ccfDNA structure would provide
a more accurate observation.
Altogether, our data suggest that ccfDNA deriving from normal tis-
sue or CRC patient tumors vary in their form, and consequently, their
mechanism of release might be different. It is difficult to hypothesize
on the high fragmentation of CRC tumor cell–derived ccfDNA, which
could result in the release of either internucleosomal breaks, as a result
of apoptosis, or large-sized ccfDNA, subsequent to necrosis or phago-
cytosis [28]. Nevertheless, these data indicate that the specific detec-
tion of KRAS-mutated ccfDNA enables its discrimination from the
WT ccfDNA through the analysis of the ccfDNA fragment size profile.
In addition, size fraction analysis could give information about the
nature of the ccfDNA release mechanism. Size fraction analysis should
be further studied by using a large cohort to validate our results and
to determine whether it might be generalized for the analysis of other
gene mutations.
Clinical Implications and Perspectives
In addition to the diagnosis and monitoring of CRC patients,
close indication of tumor evolution through the quantification of
tumor (or mutant) ccfDNA by blood testing could allow the control
and adaptation of chemotherapy or radiotherapy. mA% determina-
tion by ccfDNA analysis should be further examined in a large cohort
to study whether an mA% threshold could be defined under which
the use of targeted therapy could be beneficial. Patient monitoring by
examining KRAS/BRAF-mutant ccfDNA would be reduced to about
half of CRC cases; nevertheless, analyzing ccfDNA-bearing mutations
on other genes is likely in CRC as well as in other cancers. Deter-
mination of the mutation load might be of great interest: A recent
study demonstrated that a low proportion of malignant cells compared
to epithelial and stromal cells in CRC tumors is related to poor cancer
survival [26]. Prospective trials should further investigate the clinical
impact of this parameter and aim to evaluate whether it might also
serve as a prognostic biomarker. Targeting highly fragmented ccfDNA
revealed high level of mutant ccfDNA in a significant proportion of
CRC plasmas. This provides clues for monitoring cancer progression
with the aim of developing personalized treatment and to better cir-
cumscribe the potential biologic roles of ccfDNA-bearing specific
oncogene point mutations.
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Table W1. Treatment Received for each CRC Patient before the Blood Collection.
Sample Treatment before Blood Collection
CRC1 CT neoadjuvant 1 [oxaliplatin–5-fluorouracil (5-FU)]
CRC2 CT palliative 1 (oxaliplatin–egafur uracil–bevacizumab), CT 2 palliative
(UFT-irinotecan-bevacizumab)
CRC3 Untreated
CRC4 Untreated
CRC5 Untreated
CRC6 Untreated
CRC7 Untreated
CRC8 Untreated
CRC9 Untreated
CRC10 Untreated
CRC11 Untreated
CRC12 Untreated
CRC13 Untreated
CRC14 Untreated
CRC15 Untreated
CRC16 Untreated
CRC17 CT 1 palliative (5-FU oxaliplatin)
CRC18 CT 1 palliative (5-FU irinotecan)
CRC19 CT 1 palliative (5-FU), CT 2 palliative (5-FU avastin oxaliplatin),
CT 3 (5-FU avastin)
CRC20 CT 1 palliative (5-FU irinotecan), CT 2 palliative (5-FU irinotecan avastin),
CT 3 palliative (5-FU avastin oxaliplatin), CT 4 palliative (5-FU avastin)
CRC21 CT 1 palliative (5-FU irinotecan avastin)
CRC22 CT 1 palliative (5-FU irinotecan), CT 2 palliative (5-FU oxaliplatin), CT 3 palliative
(5-FU irinotecan avastin), CT 4 palliative (5-FU avastin)
CRC23 CT 1 palliative (irinotecan 5-FU avastin), RT 1 neoadjuvant, CT2 palliative (5-FU avastin)
CRC24 Untreated
CRC25 Untreated
CRC26 RT 1 neoadjuvant, CT 1 neoadjuvant (5-FU oxaliplatin), CT 2 neoadjuvant
(5-FU irinotecan avastin), CT 3 palliative (irinotecan avastin)
CRC27 CT 1 neoadjuvant (5-FU oxaliplatin irinotecan), RT 1 neoadjuvant
CRC28 CT 1 (Camptothecin-Erbitux)
CRC29 RT 1 neoadjuvant, CT 1 neoadjuvant
CRC30 CT 1 palliative
CRC31 CT 1 palliative
CRC32 CT 1 palliative
CRC33 Untreated
CRC34 Untreated
CRC35 Untreated
CRC36 Untreated
CRC37 Untreated
CRC38 Untreated
RT, radiotherapy; CT, chemotherapy; the number indicates the sequence of treatment.
Table W2. Characteristics of the Selected Primers and of the Amplicons Obtained.
Species Gene Primer Name Direction Sequence 5′-3′ Tm (°C) Amplicon Size (bp)
Human KRAS KRAS Hf 2 Sense AATCCGTGTGGGTCAGAGAG 59.4 189
KRAS Hr 2 Antisense GAAACAATAGCCACCCTCCTT 57.9 –
Mouse KRAS KRAS Mf 3 Sense GGCCAGGAGTGCATTAAGAC 59.4 214
KRAS Mr 3 Antisense GCACGTCAGATAGTCTCCAAA 57.9 –
Human KRAS KRAS G12V f Sense ACTTGTGGTAGTTGGAGCTGT 59.3 142
KRAS G12V r Antisense GAATGGTCCTGCACCAGTAA 58.6 –
Human BRAF BRAF V600E f Sense GATTTTGGTCTAGCTACAGA 49.7 145
BRAF V600E r Antisense TAGTAACTCAGCAGCATCTCAGG 58.8 –
Human KRAS Kras 46 Hr Antisense GCTGTATCGTCAAGGCACTC 59.4 46
Kras 82 Hr Antisense TTGGATCATATTCGTCCACAA 54.0 82
Kras 138 Hr Antisense CAAAGAATGGTCCTGCACC 56.7 138
Kras 200 Hr Antisense TGAAAATGGTCAGAGAAACCTT 54.7 200
Kras 250 Hr Antisense TGAAACCCAAGGTACATTTCAG 56.5 250
Kras 300 Hr Antisense GAACATCATGGACCCTGACA 57.3 300
Kras 350 Hr Antisense TTCTACCCTCTCACGAAACTCTG 60.6 355
Kras 400 Hr Antisense AAAGATTGTCTTTTAGGTCCAGATAGG 60.4 390
KrasNonMutated Hf Sense GTAGTTGGAGCTGGTGGC 58.2 –
Kras G13D Hf Sense GTAGTTGGAGCTGGTGA 52.8 –
Kras G12V Hf Sense TTGTGGTAGTTGGAGCTGT 54.5 –
Kras G12D Hf Sense TGTGGTAGTTGGAGCTGA 53.7 –
Kras G12S Hf Sense ACTTGTGGTAGTTGGAGCTA 55.3 –
Kras G12A Hf Sense TGTGGTAGTTGGAGCTGC 56.0 –
Intplex primers
Human BRAF Braf A1 conv k Sense TTATTGACTCTAAGAGGAAAGATGAA 56.9 105
Braf A2 conv k Antisense GAGCAAGCATTATGAAGAGTTTAGG 59.7 –
Braf V600E conv k Sense GATTTTGGTCTAGCTACAGA 53.2 97
Braf B2 conv k Antisense TAGCCTCAATTCTTACCATCCACA 59.3 –
Braf blocker Sense GCTACAGTGAAATCTCGATGG-PHO
Human KRAS Kras A1 inv k Sense GCCTGCTGAAAATGACTGA 54.5 61
Kras G12D Inv k Antisense CTCTTGCCTACGCCAT 51.7 –
Kras G12A Inv k Antisense CTCTTGCCTACGCCAG 54.3 –
Kras G12S Inv k Antisense TCTTGCCTACGCCACT 51.7 60
Kras G12C Inv k Antisense TCTTGCCTACGCCACA 51.7 –
Kras G13D Inv k Antisense GCACTCTTGCCTACGT 51.7 64
Kras G12V Inv k Antisense CTCTTGCCTACGCCAA 51.7 61
Kras B1 inv k Sense CCTTGGGTTTCAAGTTATATG 54.0 67
Kras B2 inv k Antisense CCCTGACATACTCCCAAGGA 59.4 –
Kras blocker Antisense GCCTACGCCACCAGCTC-PHO
Figure W1. Design of the primers used for the ccfDNA size distribu-
tion study.
Table W3. Numerical Values of ccfDNA Quantification Obtained in the Xenografted
Mice Experiments.
Mouse No. mWT hWT hKRASm hBRAFm Tumor Weight (mg)
1 6.336 ND ND ND 0
2 6.627 ND ND ND 0
3 13.079 0.056 ND ND 0
4 4.551 ND 0.066 ND 72.4
5 11.802 1.381 4.068 ND 89.8
6 8.29 3.644 4.304 0.201 174.8
7 3.746 2.516 1.729 ND 311.1
8 9.224 2.608 2.409 ND 358
9 6.776 1.586 6.102 0.131 465
10 5.826 8.456 7.493 0.155 543
11 9.047 9.047 12.531 0.235 1200
Data are expressed as ng/ml plasma.
ND, not determined.
Figure W2. Analysis of the sensitivity of the method for detecting
BRAF V600E point mutation. mA% represents the estimated mu-
tation load and Cq represents the quantification cycle when the
amplified amplicon is detected during the Q-PCR experiment. Each
point corresponds to a specific amplification of the targeted se-
quence as determined by melting analysis. DNA from HT29 cells
harboring a specific mutation was serially diluted six times into high
concentratedWT genomic DNA from human placenta up to dilution
of 0.2 mutated copies in 20,000 copies (1/100,000 ratio). Assay is
carried in triplicate determination.
